ZyVersa Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2200 N Commerce Pkwy Ste 208, Weston, Fl...Phone Number
(754) 231-1688Website
www.zyversa.comRevenue
-Stock Symbol
ZVSAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About ZyVersa Therapeutics
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. Our development pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat other kidney diseases, such as Alport Syndrome and Diabetic Kidney Disease. Our pipeline also includes a novel inflammasome ASC inhibitor with potential to treat multiple CNS and other inflammatory diseases.Explore more
ZyVersa Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ZyVersa Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ZyVersa Therapeutics has new funding data
Product Launch: Get notified when ZyVersa Therapeutics launches new products
Check out if ZyVersa Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at ZyVersa Therapeutics
Earning: See what the market has to say on ZyVersa Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if ZyVersa Therapeutics had a recent Job posting/layoffs
Check if ZyVersa Therapeutics has recently received funding, and reach out quickly before it becomes old news!
ZyVersa Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined ZyVersa Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to ZyVersa Therapeutics
Compare insights from companies similar to ZyVersa Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ZyVersa Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ZyVersa Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ZyVersa Therapeutics.
ZyVersa Therapeutics financials insights
Gather financial insights about ZyVersa Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
ZyVersa Therapeutics Tech Stack
A closer look at the technologies used by ZyVersa Therapeutics
Most Recent Scoops
Project
ZyVersa Therapeutics has announced that its kidney disease program (VAR-200), targeting diabetic kidney disease, is ready for Phase 2 clinical trials. The first human trials are set for Q1 2025, with interim readouts expected by Q2 2025, aiming to slow disease progression and remove cholesterol/lipids from cells.
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Project
ZyVersa Therapeutics has announced that its IC-100 inflammasome inhibitor project targets the inflammation component related to obesity, impacting multiple inflammasomes and the ASC-SPEC structure. The project aims to treat obesity holistically by reducing weight and addressing the inflammation cascade.
Research & Development, Search, Medical Research, Pharmaceuticals
Project
ZyVersa Therapeutics has announced two main projects in its portfolio: the IC-100 program, an inflammasome inhibitor nearing completion of the preclinical stage, and a kidney program ready for first patient, first dose in phase two with expected readouts mid-year 2025.
Research & Development, Search, Medical Research, Pharmaceuticals
Partnership
ZyVersa Therapeutics has partnered with key industry players, including KBI, for manufacturing. The company conducts research at University of Miami labs and has a loyalty sharing agreement with the university, while animal models are done with the university or Charles River.
Partnership, Research & Development, Search, Manufacturing Operations, Operations
Project
Partnership, Research & Development, Search, Pharmaceuticals
ZyVersa Therapeutics News & Media
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa Therapeutics, a biopharma company developing first-in-class drugs for renal and inflammatory diseases, reports 2025 financial results.ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, reports financial results for the quarter ended September 30, 2025.ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
Inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications.ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding ZyVersa Therapeutics
Sign Up For FreeTo access detailed company insights
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. Our development pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of... Read More
